Get the Stockscreener App
15.19
0.21%
-0.03
After Hours:
15.10
-0.09
-0.59%
Aurinia Pharmaceuticals Inc stock is traded at $15.19, with a volume of 893.04K.
It is down -0.21% in the last 24 hours and down -4.96% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$15.22
Open:
$15.25
24h Volume:
893.04K
Relative Volume:
0.77
Market Cap:
$1.95B
Revenue:
$298.30M
Net Income/Loss:
$298.21M
P/E Ratio:
7.0204
EPS:
2.1637
Net Cash Flow:
$166.93M
1W Performance:
-2.33%
1M Performance:
-4.96%
6M Performance:
-7.22%
1Y Performance:
+87.97%
1-Day Range:
$15.07
$15.36
1-Week Range:
$15.06
$15.99
52-Week Range:
$7.285
$16.88
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
15.19 | 1.96B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
AUPH News | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Aurinia (AUPH) Chief Legal Officer granted 115,541 performance stock units - Stock Titan
Aurinia Pharmaceuticals (AUPH) grants PSUs and stock options to CFO - Stock Titan
Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options - Stock Titan
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences - citybiz
Tranche Update on Aurinia Pharmaceuticals Inc.'s Equity Buyback Plan announced on February 15, 2024. - marketscreener.com
Why Aurinia Pharmaceuticals stock is surging Monday morning - MSN
Tangible book value per share of Aurinia Pharmaceuticals Inc. – FWB:IKAP - TradingView
Aurinia Pharmaceuticals stock (CA05156H1070): Q1 revenue beat and July earnings date in focus - AD HOC NEWS
Jefferies Upgrades Aurinia Pharmaceuticals (AUPH) - MSN
Behavioral Patterns of AUPH and Institutional Flows - Stock Traders Daily
Aurinia Pharmaceuticals (AUPH) Price Target Increased by 34.15% to 16.03 - MSN
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Raises Some Questions - simplywall.st
We Believe Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings Are A Poor Guide For Its Profitability - Yahoo Finance
Kezar Life Sciences stock (US49374L1008): Merger with Aurinia completes, shares cancelled - AD HOC NEWS
Aurinia Pharmaceuticals IncCommon Shares (NQ: AUPH - FinancialContent
Aurinia deal leaves Kezar (KZR) wholly owned as Tang Capital exits - Stock Titan
Aurinia Pharmaceuticals stock (CA05156H1070): Announces $6.955 Cash Acquisition of Kezar Life Scienc - AD HOC NEWS
AUPH stock sees biggest single-day drop in more than 9 months despite Q1 earnings beat – here’s what’s spooking investors - MSN
TradingKey - TradingKey
Kezar Life Sciences stock (US49374L1008): Aurinia completes $51.4M acquisition - AD HOC NEWS
Kezar Life Sciences (NASDAQ: KZR) COO disposes shares, options in Aurinia merger - Stock Titan
Aurinia deal cashes out Kezar (NASDAQ: KZR) CEO shares and options - Stock Titan
Kezar (KZR) director exits stake as Aurinia deal pays $6.955 plus CVRs - Stock Titan
Kezar (KZR) SVP tenders shares as Aurinia merger cancels stock options - Stock Titan
Morgan Stanley Smith Barney to sell 3.14M AUPH shares (AUPH) on 05/11/2026 - Stock Titan
AUPH (NASDAQ: AUPH) Proposed sale of 717,688 common shares - Stock Titan
500,503 AUPH shares listed for resale by Morgan Stanley (NASDAQ: AUPH) - Stock Titan
Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences By Investing.com - Investing.com Nigeria
Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences - Investing.com UK
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences - TipRanks
Kezar Life Sciences Acquired by Aurinia, Delisted From Nasdaq - TipRanks
Kezar Life Sciences acquired by Aurinia Pharma U.S.; Nasdaq delisting follows - Investing.com Nigeria
Aurinia acquires Kezar Life Sciences (NASDAQ: KZR) in cash-and-CVR deal - Stock Titan
Aurinia Pharmaceuticals (NASDAQ: AUPH) closes Kezar Life Sciences cash-and-CVR deal - Stock Titan
Aurinia (KZR) completes merger with Kezar — $6.955 per share plus CVR - Stock Titan
Aurinia to acquire Kezar Life Sciences (NASDAQ: KZR) in cash and CVR deal - Stock Titan
Aurinia Pharmaceuticals stock (CA05156H1070): Lupus drug developer eyes broader kidney disease marke - AD HOC NEWS
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Moomoo
Aurinia Pharmaceuticals Inc. Just Beat EPS By 28%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) Is Up 6.3% After Stronger Q1 LUPKYNIS-Driven Profitability Has The Bull Case Changed? - Sahm
Aurinia Pharmaceuticals (AUPH) Q1 EPS Of US$0.26 Tests Bullish Margin Narratives - Sahm
Aurinia Pharmaceuticals Sees 2026 Rev $315M-$325M >AUPH - Moomoo
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress - BioSpace
AUPH: Aurinia Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Aurinia (NASDAQ: AUPH) boosts Q1 profit, buys back stock and moves to acquire Kezar - Stock Titan
Aurinia (NASDAQ: AUPH) boosts Q1 profit, cash flow and reaffirms 2026 outlook - Stock Titan
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, Vs. FactSet Est of $0.20 - Moomoo
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):